FDA: The U.S. Food and Drug Administration today approved Raplixa (fibrin
sealant [human]), the first spray-dried fibrin sealant approved by the
agency. It is used to help control bleeding during surgery.
Raplixa
is a biological product approved for use in adults to help control
bleeding from small blood vessels when standard surgical techniques,
such as suture, ligature or cautery, are ineffective or impractical.
When applied to a bleeding site, Raplixa is dissolved in the blood and a
reaction starts between the fibrinogen and thrombin proteins. This
results in the formation of blood clots to help stop the bleeding.
Raplixa
contains fibrinogen and thrombin, two proteins found in human plasma,
the liquid portion of blood. The two protein components are individually
purified using a manufacturing process that includes virus inactivation
and removal steps to help reduce the risk for the transmission of
blood-borne viruses. The fibrin sealant components are then spray-dried,
blended and packaged in a vial. Raplixa can be applied directly from
the original product vial or by spraying with a delivery device onto a
bleeding site. It is approved for use in conjunction with an absorbable
gelatin sponge.
“This approval provides surgeons an additional
option to help control bleeding during surgery when needed,” said Karen
Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and
Research. “The spray-drying process used to manufacture Raplixa
produces dried powders that can be combined into a single vial. This
eliminates the need to combine the fibrinogen and thrombin before use
and allows the product to be stored at room temperature.”
In
support of approval, the FDA reviewed data from a clinical study
involving 719 participants, over 11 months, undergoing different types
of surgical procedures. The study demonstrated Raplixa’s effectiveness
by comparing the reduction in the time needed for bleeding to stop when
using this fibrin sealant and the time needed for bleeding to stop when
using an absorbable sponge alone.
The most commonly reported adverse reactions were surgical pain, nausea, constipation, fever and decreased blood pressure.
Raplixa is manufactured by ProFibrix BV, a wholly owned subsidiary of The Medicines Company, based in Parsippany, New Jersey.